Online inquiry

IVTScrip™ mRNA-Anti-IL13, IMA-638(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8991MR)

This product GTTS-WQ8991MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL13 gene. The antibody can be applied in Asthma research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001354991.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3596
UniProt ID P35225
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL13, IMA-638(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ8991MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12899MR IVTScrip™ mRNA-Anti-FZD10, OTSA101-DTPA(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA OTSA101-DTPA
GTTS-WQ4313MR IVTScrip™ mRNA-Anti-C1S, BIVV009(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BIVV009
GTTS-WQ3241MR IVTScrip™ mRNA-Anti-FCGRT, ARGX-113(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ARGX-113
GTTS-WQ8791MR IVTScrip™ mRNA-Anti-PCSK9, IBI-306(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IBI-306
GTTS-WQ6369MR IVTScrip™ mRNA-Anti-MSTN, CSL-362-AML(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CSL-362-AML
GTTS-WQ6832MR IVTScrip™ mRNA-Anti-IL3RA, DT-IL-3(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA DT-IL-3
GTTS-WQ15494MR IVTScrip™ mRNA-Anti-FCGRT, UCB-7665(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA UCB-7665
GTTS-WQ9900MR IVTScrip™ mRNA-Anti-CSF2, KB-003(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA KB-003
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW